Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme Expands Clinical Collaboration to Study Tazemetostat and TECENTRIQ® Combination in NSCLC

Tazemetostat and Atezolizumab to be Evaluated as New Combination in Study of Non-Small Cell Lung Cancer as Part of Genentech’s MORPHEUS Cancer Immunotherapy Platform Further Expands Tazemetostat...
June 21, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme Announces Tazemetostat Granted Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma

CAMBRIDGE, Mass., June 21, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the U.S. Food...
June 14, 2017 08:30 ET | Source: Epizyme, Inc.

Epizyme Reports Positive Interim Data from Phase 2 Trial for Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL Patients

Data Presented During Plenary Session at International Conference on Malignant Lymphoma Conference Call to be Held Today at 10:30 a.m. ET CAMBRIDGE, Mass., June 14, 2017 (GLOBE NEWSWIRE) --...
May 18, 2017 06:00 ET | Source: Epizyme, Inc.

Epizyme Announces Path Toward Tazemetostat Registration in Epithelioid Sarcoma and Reports New Clinical Data to be Presented at ASCO

Path Toward Submission for Accelerated Approval Tazemetostat Demonstrates Clinically Meaningful Activity in Epithelioid Sarcoma; Interim Phase 2 Epithelioid Sarcoma and Synovial Sarcoma Data to be...
May 08, 2017 07:00 ET | Source: Epizyme, Inc.

Epizyme Reports First Quarter 2017 Results and Provides Corporate Update

Interim Phase 2 Data of Tazemetostat in Molecularly Defined Solid Tumors and NHL to be Presented at Scientific Meetings in June Conference Call on Interim Solid Tumor Data to be Held on May 18, 2017 ...
May 04, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme Earns $10 Million Milestone Payment from GlaxoSmithKline for Initiation of GLP Toxicology Studies with Novel Methyltransferase Inhibitor

CAMBRIDGE, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced it has earned a $10...
April 25, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme Announces Tazemetostat Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML

Interim Efficacy and Safety Data from Ongoing Phase 2 Study in Follicular Lymphoma and DLBCL Selected for Plenary Presentation at the International Conference on Malignant LymphomaManagement to Host...
April 20, 2017 10:05 ET | Source: Epizyme, Inc.

Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO

CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company...
March 29, 2017 06:30 ET | Source: Epizyme, Inc.

Epizyme to Present New Preclinical Data on Tazemetostat and Epigenetic Target Identification Efforts at AACR Annual Meeting

CAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that new preclinical...
March 09, 2017 06:32 ET | Source: Epizyme, Inc.

Epizyme Reports 2016 Financial Results and Provides 2017 Pipeline Goals

Data from Tazemetostat Phase 2 Programs in NHL and Molecularly Defined Solid Tumors Planned for Medical Meetings in Second Quarter Conference Call to Be Held Today at 8:30 a.m. Eastern Time ...